The objective of the systematic review is to analyze the efficacy of direct-acting oral anticoagulants (DOAC) in the prophylaxis of thrombosis in antiphospholipid syndrome (APS). We searched for clinical trials, cohort studies and meta-analyses published from January 1, 2012 to September 30, 2022. Articles that analyzed the efficacy of DOAC in the prevention of thrombosis recurrence, with or without comparison with antivitamin K (VKA) drugs, were selected. DOACs, specifically rivaroxaban and apixaban, were significantly less effective than VKAs in preventing recurrence of thrombosis in patients with APS and prior arterial thrombosis or the concomitant presence of two or three different antiphospholipid antibodies. The proportion of patients with severe bleeding as side effect are similar in those treated with DOAC and with VKA. The results argue against the use of DOAC in the treatment of patients with thrombotic APS.
Keywords: Acenocoumarol; Acenocumarol; Anticoagulantes orales de acción directa; Antiphospholipid syndrome; Arterial thrombosis; Direct oral anticoagulants; Prevención secundaria; Secondary prevention; Síndrome antifosfolípido; Trombosis arterial; Trombosis venosa; Venous thrombosis; Warfarin; Warfarina.
Copyright © 2023 Elsevier España, S.L.U. All rights reserved.